Business
Pluri Inc.: Overview We are a biotechnology company, leveraging our proprietary cell expansion platform to develop scalable, cell-based solutions across the healthcare, food, and agriculture sectors.
Revenue increased 309.8% to $1.3M, while Net income decreased 8.1% to ($22.6M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $1.3MWatch
- Profitability — Net income ($22.6M)Watch
- Cash generation — Free cash flow ($19.8M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Leadership changes
From Pluri Inc.'s own filings, the day they're filed.
- Doron Birger · Directors · departureeff. 2025-06-30
- Liat Zalts · Chief Financial Officer · appointmenteff. 2024-09-30
- Chen Franco-Yehuda · Chief Financial Officer · departureeff. 2024-09-30
Latest filings
- 8-K · Company announcement2026-08-28
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-07-14
- 8-K · Company announcement2026-07-13
- 8-K · Company announcement2026-06-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Pluri Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.